Aurora Cannabis (TSE:ACB) Hits New 12-Month Low – Time to Sell?

Shares of Aurora Cannabis Inc. (TSE:ACB) reached a new 52-week low on Wednesday . The stock traded as low as C$5.00 and last traded at C$5.02, with a volume of 888958 shares changing hands. The stock had previously closed at C$5.55.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. ATB Capital decreased their price objective on shares of Aurora Cannabis from C$9.00 to C$8.50 and set an “outperform” rating on the stock in a research note on Thursday, December 11th. Canaccord Genuity Group set a C$10.00 target price on shares of Aurora Cannabis and gave the company a “buy” rating in a research note on Tuesday, January 27th. One investment analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of C$9.25.

Aurora Cannabis Trading Down 7.9%

The company has a market capitalization of C$287.42 million, a P/E ratio of -5.01 and a beta of 0.56. The company has a debt-to-equity ratio of 18.72, a current ratio of 3.42 and a quick ratio of 2.48. The business’s 50-day moving average price is C$6.19 and its two-hundred day moving average price is C$6.67.

Aurora Cannabis (TSE:ACB) last released its quarterly earnings data on Wednesday, November 5th. The company reported C($0.91) EPS for the quarter. The firm had revenue of C$90.37 million during the quarter. Aurora Cannabis had a negative net margin of 22.55% and a negative return on equity of 8.36%. As a group, analysts forecast that Aurora Cannabis Inc. will post -0.22 EPS for the current fiscal year.

About Aurora Cannabis

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.